Syncona’s clinical companies have screened and enrolled the first patient into a clinical trial and are scaling towards late-stage development.
Syncona’s clinical portfolio comprises companies with the potential to treat patients across a range of conditions including: non-small cell lung cancer, melanoma, adrenomyeloneuropathy, Gaucher disease and liver transplantation using a variety of modalities, including cell therapy and gene therapy.
Key facts
Unless stated all financials at 31 December 2023.
£212m
Value of clinical portfolio
5
Number of clinical trials
7
Portfolio company Board seats
Our clinical stage portfolio companies
Latest clinical stage portfolio insights
The clinical stage portfolio pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA
